• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Supporting diagnostic preparedness for detection of avian influenza A(H7N9) viruses in Europe (ECDC, April 24 2013)

Giuseppe

Emeritus
[Source: European Centre for Disease Prevention and Control (ECDC), full page: (LINK).]

Supporting diagnostic preparedness for detection of avian influenza A(H7N9) viruses in Europe

24 Apr 2013


A novel avian-origin reassortant influenza A(H7N9) virus has been detected in a number of human cases in China since March 2013. To assist European laboratories in verifying and ensuring their diagnostic capability to detect and identify this virus, ECDC jointly with CNRL and WHO Europe is releasing a technical briefing note on Diagnostic preparedness in Europe for detection of avian influenza A(H7N9) viruses.


The briefing note provides:
  • a list of laboratory preparedness considerations to ensure European-wide diagnostic capability;
  • an update on current methods used for molecular detection of human infection with avian influenza A(H7N9) virus by RT-PCR;
  • a table of H7 HA assay validation criteria;
  • information on positive controls for RT-PCR assays.
Specifically on H7 detection capabilities, the document includes the following considerations:
  • Laboratories testing for H7 will require a molecular detection capability allowing same-day specific detection ability in response to clinical queries or case scenarios.
  • A two-step approach for detection and confirmation of avian influenza A(H7N9) virus infection should be followed.
  • Laboratories require:
    • (i) a generic influenza A virus testing capability which will assuredly detect an avian influenza A(H7N9) virus within the Eurasian lineage as influenza A and
    • (ii) a specific H7 HA detection capability to confirm the presence of an avian influenza A(H7N9) virus in a sample which is positive for influenza A, but negative for H1, H3 and H5.
Further assessment and monitoring of avian influenza A(H7N9) virus detection capability in laboratories is on-going to ensure diagnostic coverage in Europe.

ECDC provides regular updates on avian influenza A(H7N9) virus, and continues to closely monitor and re-assess the situation in collaboration with WHO, US CDC, China CDC and other partners.


Related links:
External links:
-
------
 
Back
Top Bottom